RSS   Newsletter   Contact   Advertise with us
Post Online Media

Aratana appoints Brent A. Standridge as COO

AratanaAratana Therapeutics, Inc., a pet therapeutics company, announced that it has appointed Brent A. Standridge chief operating officer, a new position within Aratana.

Mr. Standridge has decades of experience in U.S. and Canadian animal health markets. Most recently, he consulted for the generic veterinary medicine maker Putney, Inc., which was acquired by Dechra Pharmaceuticals PLC in March 2016.

Article continues below

READ MORE Aratana Therapeutics adds Irvine Hockaday to board

Previously, Mr. Standridge spent 28 years with Wyeth's animal health division, Fort Dodge Animal Health, which consisted of 11 years as Senior Vice President of Sales and Marketing of North America where he was responsible for all sales and marketing activities.

While with Fort Dodge Animal Health, Mr. Standridge successfully integrated staff, products and services from animal health company acquisitions of Bristol Myers, Parke-Davis, AH Robins, American Cyanamid, Syntex Animal Health and Solvay Animal Health.

He also played an integral role during the acquisition of Wyeth by Pfizer in October 2009.

Under his leadership, his team earned Manufacturer of the Year Award and Best Overall Distributor Relations, among others. Mr. Standridge graduated from The Ohio State University with a B.S. in Animal Science.

What to read next



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy